As FDA Decision Nears, Novartis Highlights New Analysis Of Blockbuster Hopeful Inclisiran

US Decision Expected Before 2020 Ends

 
• By Andrew McConaghie

Novartis has pooled cholesterol control and safety data, but will have to wait longer for cardiovascular outcomes readout.

Basel, Switzerland - 27 August, 2016: sign on the wall of a Novartis building. Novartis International AG is a Swiss pharmaceutical company based in Basel, Switzerland.
Novartis is counting on inclisuran to be a blockbuster after its $9.7bn buyout of the drug's developer, The Medicines Company

More from Business

More from Scrip